Actavis buying Durata Therapeutics for $616.4M

SHARE Actavis buying Durata Therapeutics for $616.4M

Specialty pharmaceutical company Actavis is buying Chicago-based Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio. One of Durata’s key products is Dalvance for injection, an IV antibiotic for acute bacterial skin and skin structure infections. Dalvance was approved by the Food and Drug Administration in May.

Read more at Newsfeed.

The Latest
The Blue Devils’ seniors believe everything is back in its right place now that quarterback Adam Behrens has returned.
Cubs-Reds at Field of Dreams Stadium didn’t hook a grouchy grinch at first, but in the end it delivered.
The Cubs took an early lead, as Seiya Suzuki, Nico Hoerner and Ian Happ combined to drive in three runs in the first inning. Nick Madrigal’s fourth-inning single gave the Cubs a 4-0 lead.
The driver parked her black SUV with the dogs inside the vehicle in the 700 block of North Wells Street before entering a nearby store. Then she saw someone enter her vehicle and drive off.
The Cubs and Reds played in the second annual Field of Dreams game on Thursday. What’s the next marquee event?